The Trump administration announced Thursday the imposition of 100% tariffs on patented pharmaceuticals, a move aimed at forcing drugmakers to lower prices and relocate manufacturing to the United States. The decision marks the latest effort by President Trump to leverage tariffs as a tool to reshape corporate behavior and prioritize American interests.

Tariff Details and Incentives

Companies that commit to manufacturing drugs domestically will face a reduced tariff rate of 20%, while those entering into 'most-favored nation' pricing agreements with the White House will be exempt entirely. The policy targets pharmaceutical hubs in China, Singapore, and India, while Japan, South Korea, Switzerland, and the EU will face lower rates tied to existing trade deals. The tariffs take effect in 120 days for larger companies and 180 days for smaller firms.

'We expect all major patented pharmaceutical companies to build in the U.S.,' a senior administration official stated.

Impact on Industry

The announcement follows months of pressure on the pharmaceutical sector, which has already seen 13 companies strike deals with the administration. The new tariffs are expected to accelerate similar agreements and spark domestic investment announcements. The policy applies exclusively to branded drugs and their active ingredients, with reassessment scheduled for generic drugs and biosimilars after one year.

In a separate move, the administration adjusted tariffs on aluminum, steel, and copper, now based on the price paid by American importers rather than the production cost declared by foreign exporters. Additionally, goods containing these metals face a flat 25% tariff unless metal accounts for less than 15% of the product's weight.

These measures stem from investigations led by Commerce Secretary Howard Lutnick under Section 232 of the Trade Expansion Act, underscoring the administration's broader strategy of using tariffs to safeguard American industries and workers.